Therapeutic efficacy of tylvalosin combined with
NF-κB
Poria cocos polysaccharides (PCP)
antiviral
cytokines
pig
porcine reproductive and respiratory syndrome (PRRS)
tylvalosin
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
06
2023
accepted:
27
07
2023
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically important infectious diseases of pigs worldwide. Vaccination and various management measures have been implemented to control PRRS. However, due to high genetic diversity and insufficient understanding of the pathogenesis and immunological mechanisms, PRRS is still a challenge to the pig industry. Therefore, it is important to develop novel strategies to combat PRRS virus (PRRSV) infection. In this study, our data show that tylvalosin, a third-generation animal-specific macrolide, could inhibit PRRSV replication in MARC-145 cells, and suppress the PRRSV-induced NF-κB activation and cytokines expression. The pig infection experiment further demonstrated that tylvalosin could significantly reduce the virus loads in serum and tissues, and alleviate lung lesions of pigs infected with highly pathogenic PRRSV strains. The fever and loss of daily gain (LoDG) of the pigs were decreased as well. Considering the feature of immune suppression of PRRSV, a combination of tylvalosin with the immunopotentiator
Identifiants
pubmed: 37609059
doi: 10.3389/fvets.2023.1242146
pmc: PMC10440737
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1242146Informations de copyright
Copyright © 2023 Shi, Luo, Wang, Dai, Chen, Li, Liu, Zhang, Huang and Zhou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Virus Res. 2012 Oct;169(1):212-21
pubmed: 23073232
Arch Virol. 1993;133(3-4):477-83
pubmed: 8257302
Trends Microbiol. 2017 Dec;25(12):968-979
pubmed: 28652073
Biochem Pharmacol. 2014 Jul 1;90(1):73-87
pubmed: 24792436
Res Vet Sci. 1999 Aug;67(1):47-52
pubmed: 10425240
J Antibiot (Tokyo). 1994 Jan;47(1):80-9
pubmed: 8119865
Clin Microbiol Rev. 2010 Jul;23(3):590-615
pubmed: 20610825
Front Microbiol. 2020 Jul 28;11:1756
pubmed: 32849384
DNA Cell Biol. 2016 Oct;35(10):636-642
pubmed: 27657906
Vet Microbiol. 2015 Sep 30;179(3-4):242-9
pubmed: 26162970
Viral Immunol. 2003;16(3):335-46
pubmed: 14583148
Vet Q. 1991 Jul;13(3):121-30
pubmed: 1835211
Vet Pathol. 1998 Jan;35(1):1-20
pubmed: 9545131
Virus Res. 2010 Dec;154(1-2):7-17
pubmed: 20837072
Front Vet Sci. 2018 Apr 11;5:57
pubmed: 29696149
Front Pharmacol. 2021 Mar 19;12:649532
pubmed: 33815126
Vaccine. 2015 Aug 7;33(33):4069-80
pubmed: 26148878
Virol J. 2023 Apr 26;20(1):79
pubmed: 37101205
Virology. 2005 Nov 10;342(1):47-59
pubmed: 16129468
Transbound Emerg Dis. 2018 Aug;65(4):1078-1086
pubmed: 29520988
Biomed J. 2020 Aug;43(4):368-374
pubmed: 32563698
Toxins (Basel). 2021 May 12;13(5):
pubmed: 34065929
Clin Diagn Lab Immunol. 2004 Sep;11(5):901-8
pubmed: 15358650
Infect Genet Evol. 2017 Oct;54:279-286
pubmed: 28713014
Antiviral Res. 2018 Mar;151:63-70
pubmed: 29337166
Chem Res Chin Univ. 2013;29(2):290-293
pubmed: 32226262
J Virol. 2011 Mar;85(6):2703-13
pubmed: 21191013
PLoS One. 2007 Jun 13;2(6):e526
pubmed: 17565379
Vet Immunol Immunopathol. 1998 Feb 16;61(1):49-66
pubmed: 9613472
PLoS One. 2013;8(2):e55838
pubmed: 23409058
Vet Microbiol. 2017 May;204:35-42
pubmed: 28532803
PLoS Pathog. 2017 Feb 23;13(2):e1006206
pubmed: 28231264
Rev Med Virol. 2021 Mar;31(2):e2163
pubmed: 32969125
Virol Sin. 2010 Oct;25(5):341-51
pubmed: 20960180
Microbiol Immunol. 1996;40(7):473-9
pubmed: 8865152
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
Int J Antimicrob Agents. 2019 Apr;53(4):362-369
pubmed: 30599241
Trends Microbiol. 2020 Mar;28(3):212-223
pubmed: 31744664
Vaccine. 2015 Jun 17;33(27):3065-72
pubmed: 25980425
Virus Res. 2016 Oct 2;225:73-81
pubmed: 27663131
Virus Res. 2010 Dec;154(1-2):77-85
pubmed: 20673840
Int Immunopharmacol. 2019 Jul;72:252-257
pubmed: 31003002
Vaccines (Basel). 2021 Feb 22;9(2):
pubmed: 33671826
Vaccine. 2011 Oct 26;29(46):8192-204
pubmed: 21925560
Arch Virol. 1995;140(4):745-55
pubmed: 7794115
Drug Discov Today. 2019 Oct;24(10):2076-2085
pubmed: 31238113
Front Vet Sci. 2019 Feb 20;6:38
pubmed: 30842948
J Virol. 2016 Dec 16;91(1):
pubmed: 27795439
Vet Microbiol. 2017 Mar;201:126-135
pubmed: 28284598
Mar Drugs. 2011;9(5):844-851
pubmed: 21673893
Emerg Infect Dis. 2015 Dec;21(12):2256-7
pubmed: 26584305
Acta Pharm Sin B. 2021 Nov;11(11):3337-3363
pubmed: 34567957
Virus Res. 2019 Sep;270:197638
pubmed: 31173772
Expert Opin Drug Discov. 2023 May;18(5):551-561
pubmed: 37032577
J Virol. 2010 Sep;84(17):8700-11
pubmed: 20554771
BMC Complement Altern Med. 2014 Mar 15;14:101
pubmed: 24628870
Transbound Emerg Dis. 2016 Oct;63(5):474-9
pubmed: 27292168
Virol J. 2018 Jan 4;15(1):2
pubmed: 29301547
Vet Rec. 2012 Mar 3;170(9):225
pubmed: 22238201
Front Vet Sci. 2023 Mar 28;10:1149293
pubmed: 37056231
Int J Biol Macromol. 2016 Oct;91:248-57
pubmed: 27185068
Molecules. 2023 Feb 24;28(5):
pubmed: 36903383
Vet Pathol. 1995 Nov;32(6):648-60
pubmed: 8592800
J Gen Virol. 2016 Jun;97(6):1356-1361
pubmed: 26963602
J Virol. 2013 Jan;87(2):1159-71
pubmed: 23152505
Front Microbiol. 2023 Apr 27;14:1159590
pubmed: 37180243
Sci Rep. 2015 May 27;5:10651
pubmed: 26013676
RSC Adv. 2020 Jun 15;10(38):22783-22796
pubmed: 35514592
BMC Microbiol. 2010 May 20;10:146
pubmed: 20482897
Immunol Lett. 2011 Aug 30;138(2):137-43
pubmed: 21507332
Vet Microbiol. 2021 Sep;260:109168
pubmed: 34246042
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
Front Microbiol. 2017 Aug 28;8:1635
pubmed: 28894443
Annu Rev Anim Biosci. 2016;4:129-54
pubmed: 26646630